CARDIOGENIC SHOCK TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On October 24, 2024, Abbott, a pharmaceutical company, announced the TEAM-HF clinical trial, aiming to improve outcomes for patients with worsening heart failure. The study will enroll up to 850 patients across 75 sites and use Abbott's CardioMEMS HF System to measure pulmonary artery pressures, identifying high-risk patients who could benefit from early use of the HeartMate 3 LVAD. The trial seeks to optimize timing for advanced therapies, enhancing survival and care for heart failure patients.
• On August 9, 2024, the U.S. Food and Drug Administration approved neffy (epinephrine nasal spray) as the first non-injectable treatment for life-threatening allergic reactions (anaphylaxis) in adults and children weighing at least 66 pounds. Neffy delivers comparable effectiveness to injectable epinephrine and addresses barriers to rapid treatment, especially for patients who avoid injections.
• On May 20, 2024, Avenacy, a specialty pharmaceutical company, announced the U.S. launch of Isoproterenol Hydrochloride Injection, USP, a generic equivalent of ISUPREL, approved by the U.S. FDA. The injection treats conditions like heart block, cardiac arrest, bronchospasm during anesthesia, and cardiogenic shock. Available in 0.2 mg/mL and 1 mg/5 mL single-dose vials, it features differentiated packaging for accurate medication selection. Shipping begins this week through Avenacy’s FDA-compliant global manufacturing network.
• In December 2022, Abiomed, a medical device company’s Impella RP Flex with SmartAssist received U.S. Food and Drug Administration (FDA) pre-market approval on October 31, 2022, for treating acute right heart failure for up to 14 days. Implanted via the internal jugular vein, it enables mobility and uses dual-sensor technology for optimized management. Clinical studies show early use improves survival rates significantly. The device simplifies anticoagulant management and remains the only U.S. Food and Drug Administration-approved mechanical circulatory support (MCS) for right heart failure, addressing a critical need in underdiagnosed patients.